Janssen Expands Clinical Development for Tremfya(R) (guselkumab) in Familial Adenomatous Polyposis (FAP)

Shots:

• Janssen has initiated P-Ib proof-of-concept clinical trial assessing Guselkumab vs PBO in 72 patients with familial adenomatous polyposis (FAP). With the initiation of P-Ib study for FAP, MorphoSys will receive milestones from Janssen
• Earlier, Janssen collaborated with MorphoSys to develop Guselkumab utilizing MorphoSys’s HuCAL antibody technology (Human Combinatorial Antibody Library), a platform for invitro generation of Abs
• Tremfya(R) (guselkumab) is an anti-IL-23 mAb and has received approval in the US, Canada, EU for plaque psoriasis and in Japan for psoriasis, psoriatic arthritis & palmoplantar pustulosis

Click here to read full press release/ article | Ref: MorphoSys | Image: Twitter